Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans.

Holdt LM, Stahringer A, Sass K, Pichler G, Kulak NA, Wilfert W, Kohlmaier A, Herbst A, Northoff BH, Nicolaou A, Gäbel G, Beutner F, Scholz M, Thiery J, Musunuru K, Krohn K, Mann M, Teupser D. · 2016

Read Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. by Holdt LM, Stahringer A, Sass K, Pichler G, Kulak NA, Wilfert W, Kohlmaier A, Herbst A, Northoff BH, Nicolaou A, Gäbel G, Beutner F, Scholz M, Thiery J, Musunuru K, Krohn K, Mann M, Teupser D. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4992165.txt.

Introduction

Lesca M. Holdt leads a large team showing that a circular RNA protects against atherosclerosis by slowing ribosome production. Their study appeared in Nature Communications in 2016. The RNA, circANRIL, comes from a chromosome region long tied to cardiovascular disease risk. It is transcribed at the INK4 locus on chromosome 9p21. What it did in cells was unknown, so the team traced its binding partners in vessel wall cells and macrophages.

CircANRIL binds PES1, a factor needed to assemble ribosomes, the cell's protein factories. That grip blocks a step in ribosomal RNA maturation. The resulting nucleolar stress activates p53, which pushes the cells toward death and stops their growth, two brakes on plaque formation. The authors present circANRIL as the first clear case of a circular RNA guarding against human disease by this route.

Catalog record

CREATORHoldt LM, Stahringer A, Sass K, Pichler G, Kulak NA, Wilfert W, Kohlmaier A, Herbst A, Northoff BH, Nicolaou A, Gäbel G, Beutner F, Scholz M, Thiery J, Musunuru K, Krohn K, Mann M, Teupser D.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE71 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4992165

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans By Lesca M Holdt, Anika Stahringer, Kristina Sass, Garwin Pichler, Nils A Kulak, Wolfgang Wilfert, Alexander Kohlmaier, Andreas Herbst, Bernd H Northoff, Alexandros Nicolaou, Gabor Gäbel, Frank Beutner Published in: Nature Communications DOI: 10.1038/ncomms12429 ABSTRACT Abstract Circular RNAs (circRNAs) are broadly expressed in eukaryotic cells, but their molecular mechanism in human disease remains obscure. Here we show that circular antisense non-coding RNA in the INK4 locus (circANRIL), which is transcribed at a locus of atherosclerotic cardiovascular disease on chromosome 9p21, confers atheroprotection by controlling ribosomal RNA (rRNA) maturation and modulating pathways of atherogenesis. CircANRIL binds to pescadillo homologue 1 (PES1), an essential 60S-preribosomal assembly factor, thereby impairing exonuclease-mediated pre-rRNA processing and ribosome biogenesis in vascular smooth muscle cells and macrophages. As a consequence, circANRIL induces nucleolar stress and p53 activation, resulting in the induction of apoptosis and inhibition of proliferation, which are key cell functions in atherosclerosis. Collectively, these findings identify circANRIL as a prototype of a circRNA regulating ribosome biogenesis and conferring atheroprotection, thereby showing that circularization of long non-coding RNAs may alter RNA function and protect from human disease. Deep sequencing combined with novel bioinformatics approaches led to the discovery that a significant portion of the human transcriptome is spliced into RNA loops1,2,3. These circular RNAs (circRNAs) do not retain the exon order defined by their genomic sequence and are thought to originate from non-canonical splicing of a 5′ splice site to an upstream 3′ splice site4. Recent studies suggest that exon circularization may depend, in part, on inverted repeats or flanking intronic complementary sequences5,6 but little is known about the functions of these highly stable RNA forms. Before the finding that circRNAs are abundantly transcribed in humans, there were few reports of circRNAs in mammals. One of the earliest examples is the sex determining region of Chr Y (Sry) gene in mice, the Y chromosome encoded master regulator of the testis-determining pathway7. Sry may be expressed as circular and linear transcripts and circularization is thought to be a mechanism to escape translation7,8. Sry was also shown to serve as a competing endogenous RNA of miRNA-138 (ref. 9), and a similar ‘miRNA sponging' function has been demonstrated for a transcript antisense to cerebellar degeneration related protein 1 (CDR1as/ciRS-7)2,9. CDR1as contains ∼70 binding sites for miR-7 and acts to suppress miR-7 activity, resulting in increased levels of miR-7 target genes and functions2,9. However, only few circRNAs harbour multiple binding sites for miRNAs10, suggesting that these abundant RNAs may have other unknown regulatory functions. Previous work indicated that the long non-coding RNA (lncRNA) ANRIL(CDKN2B-AS1), which is transcribed at the cardiovascular disease risk locus on chromosome 9p21 (refs 11, 12, 13), is capable of forming RNA circles14, yet the functional relevance in human health and disease is unknown. ANRIL is differentially expressed by the genotype at 9p21 (for review see ref. 15) and increased linear ANRIL (linANRIL) was associated with increased atherosclerosis16. Recent studies suggest an important role for Alu elements in epigenetic gene regulation by linANRIL17. These Alu repeats and distal ANRIL exons are not conserved in non-primate species18, suggesting a primate-specific gain of function of this lncRNA. Here we identify a molecular effector mechanism of circular ANRIL (circANRIL) using proteomic screening, bioinformatics and functional studies. We demonstrate that circANRIL regulates the maturation of precursor ribosomal RNA (pre-rRNA), thus controlling ribosome biogenesis and nucleolar stress. In concert, circANRIL confers disease protection by modulating apoptosis and proliferation in human vascular cells and tissues, which are key cellular functions in atherosclerosis. RESULTS Association of circANRIL with atheroprotection at human 9p21 We systematically investigated the exon structure of circANRIL in human cell lines and primary cells (Fig. 1a and Supplementary Fig. 1). Using outward-facing primers and PCR analysis of reverse-transcribed RNA, we observed several species of circANRIL isoforms. The predominant circANRIL isoform consisted of exons 5, 6 and 7, where exon 7 was non-canonically spliced to exon 5 (Fig. 1a and Supplementary Fig. 1). We focused on this isoform for detailed functional characterization and further refer to it as circANRIL. CircANRIL was expressed in both healthy and diseased human vascular tissues, as well as smooth muscle cells (SMC) and monocyte/macrophages (Fig. 1b), which play an important role in atherogenesis. CircANRIL levels were relatively low compared with abundant housekeeping mRNAs such as actin beta (ACTB; Fig. 1b), but comparable to the levels of other human circular RNAs such as the previously described CDR1as2 or circular HPRT1 (circHPRT1), which was identified in the present study (Supplementary Fig. 2a). Nevertheless, circANRIL RNA levels were on average 9.7-fold higher than levels of linANRIL RNA when we analysed a panel of different human cell types and tissues (Supplementary Fig. 2a,b). CircANRIL was also more stable than linANRIL (Supplementary Fig. 3). The latter is in line with previous reports on other circular RNAs1,19. To determine the spatial distribution of circANRIL expression in the context of vascular atherogenesis, we performed RNA in situ hybridization using a circANRIL-specific probe (Fig. 1c and Supplementary Fig. 4). We detected circANRIL in SMC and in CD68-positive macrophages in human atherosclerotic plaques (Fig. 1c). [Figure: CircANRIL expression in human vascular tissue and association with atheroprotection at 9p21.(a) Schematic of circANRIL at 9p21 and qPCR assays for isoform specific quantification. CircANRIL contains exons 5, 6 and 7. Exon 7 is non-canonically spliced to exon 5. (b) qPCR analysis of circANRIL expression in human tissues, primary cells and cell lines. Beta actin (ACTB), house-keeping gene; FB, adventitial fibroblasts; HEK, HEK-293 cell line; THP1 and MonoMac, human monocytic cell line. Analyses were done in RNA pools of at least three donors. (c) In situ hybridization of circANRIL in human atherosclerotic plaque and co-localization with smooth muscle actin (SMA)-positive cells and macrophages (CD68). Sense control (CTR)-negative control. Representative staining out of three biological replicates. (d) Association of circANRIL with 9p21 haplotypes in PBMC from CAD patients. Protective (A, n=498), heterozygote (H, n=979) and risk (G, n=456) haplotypes. (e) Association of circANRIL with 9p21 haplotypes A (n=49), H (n=114) and G (n=55) in endarterectomy specimens. (f) Association of circ/linANRIL ratio in PBMC with severity of CAD (No, n=745; <50% stenosis, n=392; ≥50% stenosis, n=747). Data are given as mean±s.e.m., and associations were calculated using robust linear regression models.] We next tested for an association of circANRIL expression with the 9p21 genotype in a large cohort of patients with different burden of coronary artery disease (CAD), as assessed by coronary angiography17,20. Carriers of the CAD-protective haplotype at 9p21 showed significantly increased expression of circANRIL in peripheral blood mononuclear cells (PBMC, n=1,933; 14% per protective A-allele; Fig. 1d) and whole blood (n=970; P=1.86 × 10−7; 27% per allele; associations were calculated using robust linear regression models). Differential expression was replicated in endarterectomy specimens, where each protective allele was associated with 13% higher circANRIL expression (Fig. 1e). Importantly, the direction of effects for circANRIL was inverse to the published results for linANRIL, which was downregulated in patients carrying the 9p21 protective genotype16,17. Consistent with these findings, circANRIL expression was inversely correlated with linANRIL expression in PBMC of the CAD cohort (r=−0.24; P=3.72 × 10−29; linear regression). We then tested for an association of circANRIL with CAD burden. Patients with high circANRIL

Read the complete text